MorphoSys AG Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statement of Cash Flows

In millions of EUR, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Operating Activities:
Consolidated Net Profit / (Loss)
Adjustments to Reconcile Consolidated Net Profit / (Loss) to Net Cash Provided by / (Used in) Operating Activities:
Impairments of Assets
Depreciation and Amortization of Tangible and Intangible Assets and of Right-of-Use Assets
Net (Gain) / Loss of Other Financial Assets
Net (Gain) / Loss of Financial Assets at Amortized Cost
(Income) from Reversals of Impairments / Impairments on Financial Assets
Net (Gain) / Loss on Derivative Financial Instruments
Non Cash Effective Net Change in Financial Assets / Liabilities from Collaborations
Non Cash Effective Net Change in Financial Liabilities from Future Payments to Royalty Pharma
(Income) from Reversals of Impairments on Inventories
Gain from Deconsolidation of Subsidiaries
Net (Gain) / Loss on Sale of Property, Plant and Equipment
Non-cash Income from Recognition of previously unrecognized Intangible Assets
Recognition of Contract Liability
Gain on Repurchase and interest expense from Convertible Bond
Share-based Payment
Non Cash Income from Capitalization of Investment in Associates
Cash Income from Sales of Shares of Investment in Associates
Share of Loss of Associates accounted for using the Equity Method
Change in Fair Value Anti-Dilution Asset
Other Cash and Non-Cash Expenses (+) / Income (-)
Income Tax (Benefit) / Expenses
Changes in Operating Assets and Liabilities:
Accounts Receivable
Income Tax Receivables, Other Receivables, Inventories and Prepaid Expenses and Other Assets
Accounts Payable and Accruals, Lease Liabilities, Tax Liabilities and Provisions
Other Liabilities
Contract Liability
Income Taxes Paid (-) / Received (+)

Net Cash Provided by / (Used in) Operating Activities
Investing Activities:
Cash Payments to Acquire Other Financial Assets
Cash Receipts from Sales of Other Financial Assets
Proceeds from Sales of Bonds, Available-for-sale
Cash Payments to Acquire Other Financial Assets at Amortized Cost
Cash Receipts from Sales of Other Financial Assets at Amortized Cost
Cash Payments for Derivative Financial Instruments
Cash Receipts from Derivative Financial Instruments
Acquisitions, Net of Cash Acquired
Cash Payments to Acquire Property, Plant and Equipment
Cash Receipts from Sales of Property, Plant and Equipment
Cash Payments to Acquire Intangible Assets
Cash Payments for Acquisitions of Shares
Cash Receipts from Sales of Shares at Fair Value through Other Comprehensive Income
Cash Income from Sales of Shares of Investment in Associates
Cash Receipts from Sales of Subsidiaries
Interest Received
Net Cash Provided by / (Used in) Investing Activities

Financing Activities:
Cash Proceeds from Issuing Shares
Cash Payments for Costs from Issuing Shares
Cash Proceeds in Connection with Exercised Stock (2021) and Convertible Bonds (2020)
Cash Payments for Repurchases of own Convertible Bonds
Payment for transaction costs for repurchases of own convertible bonds
Cash Receipts (+) / Cash Payments (-) from Financing from Collaborations
Cash Receipts from Contracts with Royalty Pharma
Cash Payments for Costs in Connection with Contracts with Royalty Pharma
Cash Proceeds from Issuing Convertible Bonds
Cash Payments for Principal Elements of Lease Payments
Interest Paid
Net Cash Provided by / (Used in) Financing Activities
Effect of Exchange Rate Differences on Cash
Increase / (Decrease) in Cash and Cash Equivalents
Disposal of Cash and Cash Equivalents due to Deconsolidation of Subsidiaries
Cash and Cash Equivalents at the Beginning of the Period
Cash and Cash Equivalents at the End of the Period

Comments